SCHEDULE 13G/A: Great Point Partners and Affiliates Disclose 6.65% Stake in Vistagen Therapeutics
Beneficial Ownership Report (Schedule 13G)
Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl, have jointly reported a beneficial ownership of 6.65% in Vistagen Therapeutics, Inc., totaling 2,055,834 shares.
Summary
- Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl collectively reported beneficial ownership of 2,055,834 shares of Vistagen Therapeutics, Inc. Common Stock.
- This aggregate amount represents 6.65% of the outstanding class of securities.
- The beneficial ownership is primarily derived from warrants held by Biomedical Value Fund, L.P. (BVF) for 1,336,293 shares and Biomedical Offshore Value Fund, Ltd. (BOVF) for 719,541 shares.
- The percentage of class is calculated based on 28,862,085 shares outstanding as reported by Vistagen Therapeutics in its Form 10-Q filed on February 14, 2025, plus the 2,055,834 shares issuable upon warrant exercise.
- The reporting persons have shared voting and dispositive power over all 2,055,834 beneficially owned shares.
- A Beneficial Ownership Cap restricts the exercise of warrants if it would result in beneficial ownership exceeding 9.99% of the outstanding shares.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the company's performance or prospects. It is a neutral regulatory filing.
Risks
- The exercise of warrants is subject to a Beneficial Ownership Cap, restricting the holder and its affiliates from beneficially owning in excess of 9.99% of the outstanding shares after exercise.
Future Outlook
NA
Industry Context
This filing is a standard disclosure in the financial industry, indicating a significant ownership stake by an investment firm and its principals in a publicly traded biotechnology company, Vistagen Therapeutics. Such disclosures provide transparency regarding major shareholders and their influence.
Related Party Transactions
- Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D. (Senior Managing Member of Great Point), and Ms. Lillian Nordahl (Managing Director of Great Point) have entered into a Joint Filing Agreement to report their beneficial ownership collectively.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and potentially corporate governance.
- Company Management: Awareness of a substantial shareholder group and their potential influence on strategic decisions, although the filing states the shares are not held for control purposes.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date Vistagen Therapeutics, Inc. filed its Form 10-Q with the SEC, reporting 28,862,085 shares outstanding. |
| 03/31/2025 | Date of event which requires the filing of this Schedule 13G statement. |
| 05/15/2025 | Date of the Joint Filing Agreement between Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl. |
Keywords
Vistagen Therapeutics, Great Point Partners, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Warrants, Biomedical Value Fund, Biomedical Offshore Value Fund, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.